Severe pneumonia and acute respiratory distress syndrome are the worst outcomes in patients with COVID-19, resulting in cytokine release syndrome and multiorgan failure; the role of IL-6 in the pathological development of patients with COVID-19 has been a focus of research (7, 8), but the function of IL-6 in the course of the disease is still controversial (9–12). Here, IL6 is linked to susceptibility to pneumonia measurement.